Intervention
Icosapent ethyl
Research Observatory
Evidence Update
Current evidence
Icosapent ethyl, a prescription EPA formulation at 4 g/day, was compared with mineral-oil placebo in REDUCE-IT among 8,179 statin-treated high-risk adults with elevated triglycerides. Cardiovascular events were 17.2% versus 22.0%, while atrial-fibrillation hospitalization was 3.1% versus 2.1%. REDUCE-IT's cardiovascular benefit and STRENGTH's null result cannot be collapsed into a class-wide fish-oil claim.
What changed
REDUCE-IT found fewer cardiovascular events in its high-risk statin-treated population, with more atrial-fibrillation hospitalization; do not transfer this result to generic fish oil.
What did not change
Cross-trial differences cannot identify whether formulation, comparator or risk caused the different results.
Why it matters
Prevents fish-oil class claims and preserves formulation-specific adverse tradeoffs.
Main limitation
No head-to-head randomization; formulation, comparator and risk differ. Serious bleeding in REDUCE-IT 2.7% vs 2.1%, p=.06, is not confirmed absence of risk.
Next proof
A direct randomized comparison of specified formulations and comparators in the same risk population, with prespecified cardiovascular and safety outcomes.
Summary
Icosapent ethyl, a prescription EPA formulation at 4 g/day, was compared with mineral-oil placebo in REDUCE-IT among 8,179 statin-treated high-risk adults with elevated triglycerides. Cardiovascular events were 17.2% versus 22.0%, while atrial-fibrillation hospitalization was 3.1% versus 2.1%. REDUCE-IT's cardiovascular benefit and STRENGTH's null result cannot be collapsed into a class-wide fish-oil claim.
Intelligence Take
Prevents fish-oil class claims and preserves formulation-specific adverse tradeoffs.
Limitations
No head-to-head randomization; formulation, comparator and risk differ. Serious bleeding in REDUCE-IT 2.7% vs 2.1%, p=.06, is not confirmed absence of risk.